INTERLEUKIN-1 - BIOLOGICAL EFFECTS IN HUMAN HEMATOPOIESIS

被引：26

作者：

CROWN, J

JAKUBOWSKI, A

GABRILOVE, J

机构：

[1] Memorial Sloan-Kettering Cancer Center, NY

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 9卷 / 06期

关键词：

INTERLEUKIN-1; BIOLOGICAL EFFECTS; HEMATOPOIESIS;

D O I：

10.3109/10428199309145750

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Interleukin-1 (IL-1) produces many direct and indirect effects in hematopoiesis. Il-1 stimulates hematopoietic progenitors, and enhances production of other cytokines. Experimental data suggest a role in ameliorating the myelosuppression that occurs following, cytotoxic chemotherapy. Recombinant human interleukin-1 has now entered clinical trial. We conducted a phase I trial of IL-1beta alone, and following a myelosuppressive dose of 5-fluorouracil in patients with cancer. A prominent neutrophilia wag noted within several hours, with a later, more sustained thrombocytosis. Hypotension was dose-limiting. We observed fewer days of neutropenia following 5-FU plus IL-1 compared to IL-1 alone, but the difference did not reach statistical significance. Early results from other investigators suggest a possible protective effect from chemotherapy-induced myelosuppression. Preclinical data suggest that combinations of IL-1 and lineage specific growth factors may produce synergistic hematologic effects.

引用

页码：433 / 440

页数：8

共 52 条

[1]

Gabrilove J., Jakubowski A., Scher H., Et al., Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium, N. Engl. J. Med., 318, pp. 1414-1419, (1988)

[2]

Antman K.S., Griffin J.D., Elias A., Et al., Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression, N. Engl. J. Med., 319, pp. 593-598, (1988)

[3]

Brandt S., Peters W., Atwater S., Et al., Effect of recombinant human granulocyte-macrophage colony-stimulaling factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation, N. Engl. J. Med., 318, pp. 869-876, (1988)

[4]

Gulati S.C., Bennett C.L., Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease, Ann. Intern. Med., 116, pp. 177-182, (1992)

[5]

Advani R., Chao N., Horning S., Et al., Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma, Ann. Intern. Med., 116, pp. 183-189, (1992)

[6]

Scher H., Seidman A., Bajorin D., Et al., Escalated methotrexate, vinblastine, Adriamysin and cisplatin (E-MVAC) with granulocyte colony-stimulating factor in urothelial cancer, Proc. Am. Soc. Clin. Oncol., 11, (1992)

[7]

Gabrilove J.L., Hematopoietic growth factors, Cancer Medicine

[8]

Dinarello C.A., Interleukin-1 and interleukin-1 antagonism, Blood, 77, pp. 1627-1652, (1991)

[9]

Obal F., Opp M., Cady A.B., Et al., Interleukin-l α and an interleukin-lb˜ fragment are somonogenic, Am. J. Physiol., 259, pp. R439-R446, (1990)

[10]

Ferreira S.H., Lorenzetti B.B., Bristow A.F., Poole S., Interleukin-1b˜ as a potent hyperalgesic agent antagonized by a tripeptide analogue, Nature, 334, pp. 698-700, (1988)

← 1 2 3 4 5 6 →